Teva Pharmaceutical (TEVA) is not a company immune to controversy, but one long standing overhang might have just been removed.Last week, the global generics pharma company announced the launch of the first FDA-approved generic versions of Gilead Sciences' HIV treatments Truvada and Atripla.The launch brings to an end a patent case which stretches back to […]

The Justice Department has been investigating allegations the company colluded with other drugmakers to push up the prices of widely used pharmaceuticals, including a high cholesterol drug. “Today’s charge reaffirms that no company is too big to be prosecuted for its role in conspiracies that led to substantially higher prices for generic drugs relied on […]

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock might be going. […]

The U.S. District Court for the District of New Jersey has ruled in favor of Teva Pharmaceutical Industries Ltd. (TEVA) in a patent infringement lawsuit regarding a generic version of Narcan nasal spray for the treatment of opioid overdose.Claims from four patents related to Narcan were found to be invalid, according to the ruling by […]

We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]

Nov.25 — Teva Pharmaceuticals Industries Ltd. and other generic drugmakers have held talks with the U.S. Justice Department about resolving a criminal anti-trust probe of alleged price fixing by the companies. Bloomberg’s Kailey Leinz reports on “Balance of Power.”

The number of pharmaceutical and biotechnology companies seeking Chapter 11 protection has nearly tripled the 10-year average in 2019 and is expected to continue to rise Continue reading…